Journal
ADVANCES IN RADIATION ONCOLOGY
Volume 3, Issue 4, Pages 520-526Publisher
ELSEVIER INC
DOI: 10.1016/j.adro.2018.08.018
Keywords
-
Funding
- National Cancer Institute [R01CA182311, R01CA208644]
Ask authors/readers for more resources
Immunotherapy is reshaping cancer treatment paradigms; however, response rates to immune therapies are low and depend on the host's pre-existing antitumor immunity. The tumor microenvironment is comprised of malignant cells, stroma, and extracellular molecules and can hinder immune control of tumors. Herein, we review how anti-tumor immune responses are formed and how tumors avoid immune destruction. We also outline potential therapeutic targets in the immunosuppressive tumor microenvironment to promote immune control of tumors. (C) 2018 The Authors. Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available